RetinaLyze International

RetinaLyze International Safe, fast and efficient retinal investigations with RetinaLyze AI and Telemedicine.

Ask a chain's clinical director about screening quality and they'll tell you about their best store.Ask about the twelft...
02/09/2026

Ask a chain's clinical director about screening quality and they'll tell you about their best store.

Ask about the twelfth-best. The conversation changes.

Variance is the real problem in a network. Not whether screening can be done well. It clearly can! Whether it's done the same way in Aarhus on a Tuesday and in Milan on a Saturday. By someone three weeks into the job. At five o'clock, when it's been a long day.

Chains don't lose on their ceiling. They lose on their floor.

That's the argument for automating the read rather than the capture. When the analysis takes 45 seconds and comes back the same every time, your variable is the image, not the interpretation. And image quality is a training problem. You can manage that.

Across 7 million screenings, consistency is what multi-site groups actually raise with us. More than accuracy.

It changes the commercial picture too. Screening stops being something your strongest practitioners offer and becomes something the network does. That's the version that shows up in a P&L.

If you run multi-site: what's the spread between your best and worst store? And do you measure it?

The EU AI Act deadline passed. Plenty of eye care practices spent August worrying about a date that doesn't apply to the...
31/08/2026

The EU AI Act deadline passed. Plenty of eye care practices spent August worrying about a date that doesn't apply to them.

Screening software is a medical device. That puts it under Annex I. And the high-risk rules in Article 6(1) don't kick in until August 2027. Your CE-marked tool didn't stop being compliant this month. You're fine!

But there is a rule that's already live, and almost nobody mentions it. AI literacy.

Since February 2025, if you deploy an AI system, you have to make sure your people understand it. What it does. What it doesn't. How to read what comes back. You can't buy that from a vendor. It's a training record for the optometrist, the technician, and whoever ends up explaining a yellow result to a nervous patient.

We built RetinaLyze around that. Colour-coded results a trained operator reads in seconds. A clear referral route when they shouldn't be reading it alone. Documentation that holds up in an audit.

So the question for your vendor isn't "are you compliant?" It's "what do I need to prove about my own staff?"

Has your practice done anything about AI literacy yet? Most haven't.

You are often the first person who gets a proper look at the retina.Not when the patient is already in the hospital syst...
26/08/2026

You are often the first person who gets a proper look at the retina.

Not when the patient is already in the hospital system.
Not when symptoms have become obvious.
But during a routine visit, where the patient may simply be there for new glasses, contact lenses, or a general eye check.

That position matters more than it is sometimes given credit for.
As an optometrist, you are not expected to diagnose every retinal disease. But you are often in the best position to notice when something does not look right.

A small haemorrhage.
An unusual optic nerve head.
Macular changes.
Poor image quality that needs repeating.
A symptom that does not match the image.

These are the moments where good screening makes a difference. Not because every finding is dramatic or every patient needs referral.

But because someone looked carefully, asked the right questions, and made sure the next step was not left to chance.

AI-supported retinal screening can help structure that process.
But the clinical awareness starts with you.

Sometimes the most important part of a retinal image is what wasn’t visible on the previous one.This left-eye case shows...
24/08/2026

Sometimes the most important part of a retinal image is what wasn’t visible on the previous one.

This left-eye case shows a retinal detachment with pale, wave-like folds across the detached retina, creating an almost sand-dune-like pattern.

What makes the case particularly interesting is the comparison. Just three weeks earlier, the 45° central fundus images showed no visible signs of retinal detachment.

It is a useful reminder of the limitations of a central fundus image. A retinal detachment may begin outside the captured field, and the picture can change significantly over a relatively short period of time.

That is why symptoms, clinical history and peripheral assessment still matter, even when a recent central image looked unremarkable.

19/08/2026

A bump in the retina can tell a much bigger story 👁️

A pigment epithelial detachment (PED) occurs when the retinal pigment epithelium (RPE) separates from the underlying Bruch’s membrane. Depending on what lies beneath the RPE, a PED may be drusenoid, serous, fibrovascular or a combination.

On a colour fundus image, a PED may appear as an elevated or discoloured area in the macula. But the image alone may not reveal what is underneath the elevation or whether neovascular activity is present.

That is where additional imaging can become important. OCT provides a cross-sectional view of the retina, making it possible to characterize the shape and contents of a PED much more precisely.

PEDs are particularly relevant in age-related macular degeneration (AMD). Drusenoid PEDs are commonly associated with non-neovascular AMD, while vascularized PEDs can occur with neovascular AMD and may carry a greater risk of visual loss.

It is a good reminder that retinal screening is not always about identifying a single obvious lesion. Sometimes, the important finding is the one that tells us further investigation is needed.

RetinaLyze AMD supports eye care professionals by analysing colour fundus images for retinal lesions that may indicate early signs of AMD as part of the overall clinical assessment.

RetinaLyze OCT can detect more than 75 pathological signs, including epithelium detachment, helping eye care professionals identify findings that may require further attention.

Peripapillary atrophy (PPA) is an area of atrophy around the optic nerve head. It is often seen in myopic eyes and can a...
17/08/2026

Peripapillary atrophy (PPA) is an area of atrophy around the optic nerve head. It is often seen in myopic eyes and can also be associated with glaucoma.
However, PPA itself does not mean that a patient has glaucoma.

What it can do is make glaucoma assessment more challenging.

On a retinal image, pronounced PPA can make the border of the optic disc harder to define and complicate the evaluation of structures such as the neuroretinal rim and retinal nerve fiber layer. In some cases, even automated optic-disc margin detection can struggle when PPA is present.

This is one reason why detecting glaucoma from fundus images is more complex than simply looking at the cup-to-disc ratio.

At RetinaLyze, the Glaucoma algorithm takes a different approach, assessing hemoglobin levels in the optic nerve head to evaluate signs associated with glaucoma.

12/08/2026

7 million eye screenings with AI and telemedicine since 2013!

RetinaLyze helps make early detection of eye disease more accessible - one screening at a time.

We were recently asked an interesting question:Can AI safely handle all negative cases in an eye screening pathway, whil...
10/08/2026

We were recently asked an interesting question:

Can AI safely handle all negative cases in an eye screening pathway, while only positive results are reviewed by a human grader before referral?

Our answer was: broadly, yes. But it is a little more nuanced than that.

The real value of AI in screening is that it can remove a large proportion of clearly negative cases from the traditional human workflow. This allows human graders and ophthalmologists to focus their time on cases that are positive, uncertain, ungradable or otherwise need closer attention.

But that does not mean every negative case should automatically disappear from human oversight.

A safe workflow still needs to consider image quality, patients outside the system’s intended use, unexplained symptoms, changes in visual acuity and other findings that may not be covered by the AI analysis.

It also makes sense to audit a proportion of negative cases as part of ongoing quality assurance.

And here is the important part:
You can still achieve significant time savings, even if some negative cases continue to be reviewed.

The benefit of AI does not depend on creating a fully autonomous pathway from day one. AI can help prioritise cases, reduce the number of images requiring detailed assessment and make routine reviews much faster.

In practice, the best model is often not “AI or humans."
Instead: AI, graders and ophthalmologists working together, with each handling the cases where they add the most value.

One of the biggest mistakes in retinal screening is treating “normal” as the most important result.It is not!The most im...
05/08/2026

One of the biggest mistakes in retinal screening is treating “normal” as the most important result.

It is not!

The most important result is often the one that creates uncertainty.

A small haemorrhage.
A borderline optic disc.
A few drusen.
An OCT finding that does not quite match the symptoms.
An image that is technically acceptable, but not quite good enough to fully trust.

This is where clinical work actually happens.

Green results are reassuring.
Red results are usually easier to act on.
But the grey zone is where judgement matters most.

That is also where screening workflows need to be strongest.

What should be repeated?
What should be monitored?
What should be referred?
What needs ophthalmology review?
What should be explained carefully to the patient without creating unnecessary concern?

AI-supported analysis can help structure this process, but it should not pretend that every clinical question has a simple answer.

In eye care, uncertainty is not a failure of the system, but part of the work.

The value of good screening is not only finding obvious disease. It is helping clinicians handle the borderline cases more consistently, with better documentation and a clearer next step.

I think we sometimes talk about AI in eye care in the wrong order.We start with the algorithm.How sensitive is it?How sp...
03/08/2026

I think we sometimes talk about AI in eye care in the wrong order.
We start with the algorithm.

How sensitive is it?
How specific is it?
Which diseases can it detect?
How fast is it?

Those questions matter, of course. But they are not usually what decides whether a tool becomes useful in daily practice.

The real question is often more related to humans and usage:
Will clinicians actually trust it enough to use it?
Will staff remember to use it on a busy day?
Will the result make the next step clearer, or just create more uncertainty?
Will the patient leave with a better understanding of their eye health?

After working with AI-supported retinal screening for many years, my view is that adoption is rarely about technology alone - and more about workflow, confidence, and clinical relevance.

A good AI tool should not ask clinicians to change everything around it. It should fit quietly into the way eye care is already delivered, support better decisions, and know its place.

Not every image needs a dramatic conclusion.
Not every result needs a referral.
Not every finding can be reduced to green, yellow, or red.
That nuance is exactly why clinicians still matter.

AI can help us screen more consistently, document more clearly, and identify patients who may need attention earlier. But the value only appears when it supports the professional in front of the patient.

That is where I think the future of AI in eye care will be decided. Not in the demo, but in the clinic.

// Ganesh Ram, CCO, RetinaLyze

Adresse

Lyskær 1
Skovlunde
2730

Hvad er åbningstiderne?

Mandag 09:00 - 17:30
Tirsdag 09:00 - 17:30
Onsdag 09:00 - 17:30
Torsdag 09:00 - 17:30
Fredag 09:00 - 17:30

Internet side

Underretninger

Vær den første til at vide, og lad os sende dig en email, når RetinaLyze International sender nyheder og tilbud. Din e-mail-adresse vil ikke blive brugt til andre formål, og du kan til enhver tid afmelde dig.

Kontakt Virksomheden

Send en besked til RetinaLyze International:

Genveje

Del